Celldex Therapeutics Inc. (NASDAQ:CLDX) shares dropped 3.4% during mid-day trading on Thursday . The company traded as low as $4.49 and last traded at $4.50, with a volume of 1,030,063 shares. The stock had previously closed at $4.66.

CLDX has been the topic of a number of recent research reports. Jefferies Group restated a “hold” rating and issued a $4.00 price target on shares of Celldex Therapeutics in a research report on Friday, May 6th. Cowen and Company restated an “outperform” rating and issued a $12.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, April 19th. Roth Capital restated a “buy” rating and issued a $7.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, April 19th. Finally, Wedbush restated a “neutral” rating and issued a $3.00 price target on shares of Celldex Therapeutics in a research report on Friday, May 6th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $14.11.

The company has a 50 day moving average price of $4.56 and a 200-day moving average price of $5.12. The company’s market cap is $460.03 million.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.35). During the same period last year, the firm posted ($0.33) EPS. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.06 million. The company’s revenue was up 160.0% compared to the same quarter last year. Analysts anticipate that Celldex Therapeutics Inc. will post ($1.36) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Celldex Therapeutics stock. Rhumbline Advisers raised its stake in shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) by 4.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,426 shares of the biopharmaceutical company’s stock after buying an additional 5,110 shares during the period. Rhumbline Advisers owned about 0.11% of Celldex Therapeutics worth $1,700,000 at the end of the most recent quarter.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.